Abstracts tagged "Autoinflammatory Disease and Janus kinase (JAK)"

Abstract Number: 1782 • 2013 ACR/ARHP Annual Meeting
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperatures (CANDLE): Clinical Characterization and Initial Response To Janus Kinase Inhibition With Baricitinib
Gina A. Montealegre Sanchez¹, Adam L. Reinhardt², Paul Brogan³, Yackov Berkun⁴, Diane Brown⁵, Peter Chira⁶, Ling Gao⁷, Dawn C. Chapelle¹, Nicole Plass¹, Hanna Kim¹, Michael Davis⁸, Adriana Almeida de Jesus⁸, Yin Liu¹, Yan Huang¹, Colleen Hadigan⁹, Theo Heller¹⁰, Zlotogorski Zlotogorski¹¹, John J. O'Shea¹², Chyi-chia Lee¹³, Suvimol C. Hill¹⁴, Kristina Rother¹⁵, Massimo Gadina¹⁶ and Raphaela T. Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁴Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁵Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ⁶Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ⁷Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁹National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, ¹⁰National Institute of Diabetes and Digestive Kidney Diseases, NIH, Bethesda, MD, ¹¹Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Jerusalem, Israel, ¹²NIAMS, Bethesda, MD, ¹³National Cancer Institute, National Institutes of Health, Bethesda, MD, ¹⁴Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ¹⁵Pediatric Diabetes & Metabolism, National Institute of Diabetes and Digestive Kidney Diseases, NIH, Bethesda, MD, ¹⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: CANDLE, a novel autoinflammatory syndrome presents with attacks of fever, annular cutaneous plaques, persistent periorbital edema, arthritis, lymphopenia and lipodystrophy since early childhood. CANDLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].